173 related articles for article (PubMed ID: 36397118)
1. Effect of an enteral amino acid blend on muscle and gut functionality in critically ill patients: a proof-of-concept randomized controlled trial.
Heming N; Carlier R; Prigent H; Mekki A; Jousset C; Lofaso F; Ambrosi X; Bounab R; Maxime V; Mansart A; Crenn P; Moine P; Foltzer F; Cuenoud B; Konz T; Corthesy J; Beaumont M; Hartweg M; Roessle C; Preiser JC; Breuillé D; Annane D
Crit Care; 2022 Nov; 26(1):358. PubMed ID: 36397118
[TBL] [Abstract][Full Text] [Related]
2. The effects of synbiotic supplementation on enteral feeding tolerance, protein homeostasis, and muscle wasting of critically ill adult patients: a randomized controlled trial.
Seifi N; Rezvani R; Sedaghat A; Nematy M; Khadem-Rezaiyan M; Safarian M
Trials; 2022 Oct; 23(1):846. PubMed ID: 36195945
[TBL] [Abstract][Full Text] [Related]
3. Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Clinical Trial.
Pickkers P; Mehta RL; Murray PT; Joannidis M; Molitoris BA; Kellum JA; Bachler M; Hoste EAJ; Hoiting O; Krell K; Ostermann M; Rozendaal W; Valkonen M; Brealey D; Beishuizen A; Meziani F; Murugan R; de Geus H; Payen D; van den Berg E; Arend J;
JAMA; 2018 Nov; 320(19):1998-2009. PubMed ID: 30357272
[TBL] [Abstract][Full Text] [Related]
4. Feeding the critically ill obese patient: a systematic review protocol.
Secombe P; Harley S; Chapman M; Aromataris E
JBI Database System Rev Implement Rep; 2015 Oct; 13(10):95-109. PubMed ID: 26571286
[TBL] [Abstract][Full Text] [Related]
5. Intravenous amino acid therapy for kidney function in critically ill patients: a randomized controlled trial.
Doig GS; Simpson F; Bellomo R; Heighes PT; Sweetman EA; Chesher D; Pollock C; Davies A; Botha J; Harrigan P; Reade MC
Intensive Care Med; 2015 Jul; 41(7):1197-208. PubMed ID: 25925203
[TBL] [Abstract][Full Text] [Related]
6. Effect of curcumin-pipeine supplementation on clinical status, mortality rate, oxidative stress, and inflammatory markers in critically ill ICU patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Askari G; Alikiaii B; Soleimani D; Sahebkar A; Mirjalili M; Feizi A; Iraj B; Bagherniya M
Trials; 2021 Jul; 22(1):434. PubMed ID: 34229742
[TBL] [Abstract][Full Text] [Related]
7. Impact of β-hydroxy-β-methylbutyrate (HMB) on muscle loss and protein metabolism in critically ill patients: A RCT.
Viana MV; Becce F; Pantet O; Schmidt S; Bagnoud G; Thaden JJ; Ten Have GAM; Engelen MPKJ; Voidey A; Deutz NEP; Berger MM
Clin Nutr; 2021 Aug; 40(8):4878-4887. PubMed ID: 34358832
[TBL] [Abstract][Full Text] [Related]
8. Protein delivery in intermittent and continuous enteral nutrition with a protein-rich formula in critically ill patients-a protocol for the prospective randomized controlled proof-of-concept Protein Bolus Nutrition (Pro BoNo) study.
Reinhold S; Yeginsoy D; Hollinger A; Todorov A; Tintignac L; Sinnreich M; Kiss C; Gebhard CE; Kovács B; Gysi B; Imwinkelried L; Siegemund M
Trials; 2020 Aug; 21(1):740. PubMed ID: 32843075
[TBL] [Abstract][Full Text] [Related]
9. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial.
Pickkers P; Heemskerk S; Schouten J; Laterre PF; Vincent JL; Beishuizen A; Jorens PG; Spapen H; Bulitta M; Peters WH; van der Hoeven JG
Crit Care; 2012 Jan; 16(1):R14. PubMed ID: 22269279
[TBL] [Abstract][Full Text] [Related]
10. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
Jones D; Boudes PF; Swain MG; Bowlus CL; Galambos MR; Bacon BR; Doerffel Y; Gitlin N; Gordon SC; Odin JA; Sheridan D; Wörns MA; Clark V; Corless L; Hartmann H; Jonas ME; Kremer AE; Mells GF; Buggisch P; Freilich BL; Levy C; Vierling JM; Bernstein DE; Hartleb M; Janczewska E; Rochling F; Shah H; Shiffman ML; Smith JH; Choi YJ; Steinberg A; Varga M; Chera H; Martin R; McWherter CA; Hirschfield GM
Lancet Gastroenterol Hepatol; 2017 Oct; 2(10):716-726. PubMed ID: 28818518
[TBL] [Abstract][Full Text] [Related]
11. Indications and contraindications for infusing specific amino acids (leucine, glutamine, arginine, citrulline, and taurine) in critical illness.
Ginguay A; De Bandt JP; Cynober L
Curr Opin Clin Nutr Metab Care; 2016 Mar; 19(2):161-9. PubMed ID: 26828584
[TBL] [Abstract][Full Text] [Related]
12. Effect of Intermittent or Continuous Feed on Muscle Wasting in Critical Illness: A Phase 2 Clinical Trial.
McNelly AS; Bear DE; Connolly BA; Arbane G; Allum L; Tarbhai A; Cooper JA; Hopkins PA; Wise MP; Brealey D; Rooney K; Cupitt J; Carr B; Koelfat K; Damink SO; Atherton PJ; Hart N; Montgomery HE; Puthucheary ZA
Chest; 2020 Jul; 158(1):183-194. PubMed ID: 32247714
[TBL] [Abstract][Full Text] [Related]
13. Microbial cell preparation in enteral feeding in critically ill patients: A randomized, double-blind, placebo-controlled clinical trial.
Malik AA; Rajandram R; Tah PC; Hakumat-Rai VR; Chin KF
J Crit Care; 2016 Apr; 32():182-8. PubMed ID: 26777745
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
15. Is the amino acid pattern in medical nutrition therapy crucial for successfully attenuating muscle mass loss in adult ICU patients? Secondary analysis of a RCT.
Dresen E; Siepmann L; Weißbrich C; Weinhold L; Putensen C; Stehle P
Clin Nutr ESPEN; 2022 Feb; 47():36-44. PubMed ID: 35063228
[TBL] [Abstract][Full Text] [Related]
16. Medical high-protein nutrition therapy and loss of muscle mass in adult ICU patients: A randomized controlled trial.
Dresen E; Weißbrich C; Fimmers R; Putensen C; Stehle P
Clin Nutr; 2021 Apr; 40(4):1562-1570. PubMed ID: 33743292
[TBL] [Abstract][Full Text] [Related]
17. Metabolic effects of enteral versus parenteral alanyl-glutamine dipeptide administration in critically ill patients receiving enteral feeding: a pilot study.
Luo M; Bazargan N; Griffith DP; Estívariz CF; Leader LM; Easley KA; Daignault NM; Hao L; Meddings JB; Galloway JR; Blumberg JB; Jones DP; Ziegler TR
Clin Nutr; 2008 Apr; 27(2):297-306. PubMed ID: 18258342
[TBL] [Abstract][Full Text] [Related]
18. Citrulline and muscle protein homeostasis in three different models of hypercatabolism.
Kuçi O; Verlaan D; Vicente C; Nubret E; Le Plenier S; De Bandt JP; Cynober L
Clin Nutr; 2020 Mar; 39(3):917-927. PubMed ID: 31010700
[TBL] [Abstract][Full Text] [Related]
19. Effect of specific amino acids on hepatic lipid metabolism in fructose-induced non-alcoholic fatty liver disease.
Jegatheesan P; Beutheu S; Ventura G; Sarfati G; Nubret E; Kapel N; Waligora-Dupriet AJ; Bergheim I; Cynober L; De-Bandt JP
Clin Nutr; 2016 Feb; 35(1):175-182. PubMed ID: 25736031
[TBL] [Abstract][Full Text] [Related]
20. Acute intestinal failure in critically ill patients: is plasma citrulline the right marker?
Piton G; Manzon C; Cypriani B; Carbonnel F; Capellier G
Intensive Care Med; 2011 Jun; 37(6):911-7. PubMed ID: 21400011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
